The Society Citation is a discretionary award given in recognition of exemplary contributions to IDSA and outstanding discovery in the field of infectious diseases or a lifetime of outstanding achievement. More than one award may be given each year.
2023 Winners: Dimitrios P. Kontoyiannis, MD, ScD, FIDSA, and Robert T. Schooley, MD, FIDSA
Dimitrios P. Kontoyiannis, MD, ScD, FIDSA, is among the world’s most impactful scholars in medical/translational mycology. His prolific laboratory and clinical research places him at the forefront of discovery in antifungal chemotherapy, model systems to study drug resistance mechanisms, aspergillosis and zygomycosis. Dr. Kontoyiannis has also contributed to research in candidemia, diagnostic and laboratory model studies, and the non-mycologic subjects of cytomegalovirus, adenovirus and nocardiosis.
Dr. Kontoyiannis joined the University of Texas MD Anderson Cancer Center in 1998 after completing his training. Currently, he is the Robert C. Hickey Chair in Clinical Care and Deputy Head for Research in the Division of Internal Medicine there. Dr. Kontoyiannis is also an adjunct professor in the Division of Pharmacology at the University of Houston, the Department of Infectious Diseases at the Baylor College of Medicine and UT Health School of Public Health.
The author of more than 670 peer-reviewed publications, Dr. Kontoyiannis’ work has 67,800 citations and an H index of 127 (Google Scholar, as of Aug. 31, 2023). His laboratory research includes using innovative mini-host models (flies), murine models and in-vitro platforms, and has provided insights on fungal pathobiology, immunopathogenesis, resistance, the mode of action of antifungals, antifungal drug discovery, novel diagnostics, fungal pharmacotherapy and immunotherapy.
Dr. Kontoyiannis’ clinical research covers epidemiology, risk factors, prevention, diagnosis, prognosis and management of virtually all opportunistic yeast and mold infections afflicting patients with malignancy and/or cell transplantation. The National Institutes of Health, the Centers for Disease Control and Prevention, industry and the MD Anderson Cancer Center have all funded his research.
A fellow of IDSA, Dr. Kontoyiannis serves or has served on the IDSA Planning Committee, the Executive Committee Interest Group for Transplant Recipients and Immunocompromised Hosts, and the Aspergillosis Guidelines Committee. He is a frequent speaker or panelist at IDWeek. Dr. Kontoyiannis is also a fellow of the American College of Physicians, the European Society of Clinical Microbiology and Infectious Diseases and the Royal College of Physicians. He is a fellow-elect of the American Academy of Microbiology.
Dr. Kontoyiannis has received many institutional, national and international awards, including the American Society for Microbiology award for Outstanding Research in the Pathogenesis of Microbial Diseases (mentor), the Medical Mycological Society of the Americas’ Billy Cooper Memorial award, the European Confederation of Medical Mycology’s Drouhet Medal and the Mycology Society of New York’s Littman award.
For his many contributions to advancing medical/translational mycology, IDSA is delighted to add a 2023 Society Citation Award to Dr. Kontoyiannis’s numerous other honors.
Robert T. Schooley, MD, FIDSA, helped shape national and local public health decisions related to COVID-19 as editor-in-chief of IDSA’s Clinical Infectious Diseases from 2017 to 2022. The journal published many of the essential papers that guided scientists early in the COVID-19 pandemic. In 2021, CID was the most cited infectious diseases journal.
Dr. Schooley is a distinguished professor of medicine in the Division of Infectious Diseases and Global Public Health at the University of California-San Diego and the former chief of the Division of Infectious Diseases. Earlier in his career, Dr. Schooley was a faculty member at Harvard Medical School and the University of Colorado Health Sciences Center.
Despite receiving more than double the volume of submissions during the pandemic, Dr. Schooley ensured that peer review remained intact and that CID published only the highest quality science. Under his leadership, the journal’s impact factor, immediacy index, citations and readership all increased.
Between 2016 and 2020, CID’s impact factor increased from 8.216 to 9.079; the immediacy index increased from 2.958 to 16.211; and the number of citations increased from 58,143 to 89,276. In 2021, the journal’s impact factor reached an all-time high of 20.999, based on more than 115,000 citations. This was nearly double the number of citations that the second most-cited journal received.
In 2020, the online readership for CID increased by 49% compared to 2019. Readership remained 30% above 2019 levels in 2021. Dr. Schooley was a member of the editorial board of CID for 20 years.
As chief of the Division of Infectious Diseases at the University of California-San Diego, Dr. Schooley helped San Diego control an outbreak of hepatitis A virus in its homeless population, guided the city through its response to the COVID-19 pandemic and led an effort to bring phage therapy to patients who have multidrug-resistant infections that are untreatable with antibiotics.
Dr. Schooley’s research focuses on the pathogenesis and therapy of RNA virus infections. He has been heavily involved in the development of antiviral chemotherapy directed at HIV, hepatitis C virus and the herpes group of viruses. Under Dr. Schooley’s leadership from 1995 until 2002, the National Institutes of Health’s AIDS Clinical Trials Group conducted many of the seminal studies that defined modern antiretroviral chemotherapy. Dr. Schooley also expanded the group’s focus from the U.S. to the world. He is also involved with research, teaching and infrastructure building efforts in sub-Saharan Africa.
IDSA is pleased to honor Dr. Schooley with a 2023 Society Citation Award for his contributions to the understanding of COVID-19 and the public health decisions that were made as well as his reserach on modern antiretroviral chemotherapy.
Past Society Citation Award Winners
| 2022 |
John Brooks, MD |
| 2021 |
Dial Hewlett, Jr., MD, FIDSA |
| 2020 | Adarsh Bhimraj, M.D., FIDSA |
| 2020 | Christopher A. Ohl, M.D., FIDSA |
| 2019 | Brian S. Schwartz, MD |
| Steven K. Schmitt, MD, FIDSA | |
| 2018 | Louis D. Saravolatz, MD, FIDSA |
| 2017 | Wendy S. Armstrong, MD, FIDSA Patrick Joseph, MD, FIDSA Dean, L. Winslow, MD, FIDSA |
| 2016 | Mark A. Leasure Bruce G. Gellin, MD, MPH, FIDSA Martin G. Myers, MD, FIDSA, FPIDS |
| 2015 | Helen W. Boucher, MD, FIDSA |
| 2014 | David L. Thomas MD, MPH, FIDSA |
| 2013 | Marguerite A. Neill, MD Catherine M. Wilfert, MD |
| 2012 | Myron S. Cohen, MD, FIDSA N. Cary Engleberg, MD, FIDSA Alan D. Tice, MD, FIDSA, FSHEA |
| 2011 |
Carol J. Baker, MD, FIDSA |
| 2010 |
John G. Bartlett, MD, FIDSA |
| 2009 | Warren D. Johnson, Jr., MD, FIDSA |
| 2008 | Russell Petrak, MD |
| 2007 |
Gary P. Wormser, MD, FIDSA |
| 2006 |
Larry J. Strausbaugh, MD, FIDSA |
| 2005 |
George G. Jackson, MD |
| 2004 |
Stanley Falkow, PhD |
| 2003 | Morton N. Swartz, MD Julie Gerberding, MD, on behalf of the CDC staff |
| 2002 | Marvin Turck, MD C. Douglas Webb, PhD |
| 2001 | George W. Counts, MD |
| 2000 | Dennis George Maki, MD Dennis L. Stevens, MD, PhD |
| 1999 | Sydney Finegold, MD |
| 1998 | Porter Anderson, PhD John Robbins, MD Rachel Schneerson, MD David Smith, MD |
| 1997 | Johan Septimus Bakken, MD |
| 1996 | Donald A. Henderson, MD |
| 1995 | King Holmes, MD, PhD |
| 1994 | David Rogers, MD Edward Hook, III, MD |
| 1993 | Dorothy Horstmann, MD Samuel Katz, MD Harold Neu, MD |
| 1992 | Robert Austrian, MD Jay Sanford, MD |
| 1988 | Martha Yow, MD |
| 1987 | Margaret Pittman, PhD, MS |
| 1986 | Victor Nussenzweig, MD |
| 1985 | Robert Gallo, MD Luc Montagnier, CNRS Sheldon Wolff, MD |
| 1984 | Allen Steere, MD |
| 1983 | Maurice Hilleman, PhD Saul Krugman, MD |
| 1982 | James Todd, MD |
| 1981 | Don Brenner, MS, PhD William Cherry MS, PhD and Colleagues James Freeley, PhD Joseph McDade, PhD |
| 1977 | Edward Kass, MD, PhD, M |